GNRH1 and prostate carcinoma: Pharmacologic LHRH drug development over the years demonstrated that chronic administration of synthetic long-acting analogs of the luteinizing hormone–releasing hormone (LH–RH) resulted in suppression of Leydig cell function, leading to the first use of these agents in the treatment of prostate cancer [5].